Literature DB >> 22897519

Plasma indoleamine 2,3-dioxygenase and arginase type I may contribute to decreased blood T-cell count in hemodialysis patients.

Theodoros Eleftheriadis1, Efi Yiannaki, Georgia Antoniadi, Vassilios Liakopoulos, Georgios Pissas, Grammati Galaktidou, Ioannis Stefanidis.   

Abstract

BACKGROUND: Acquired immunity is impaired in hemodialysis (HD) patients, and decreased T-cell number may contribute. Indoleamine 2,3-dioxygenase (IDO) and arginase type I (ARG) catabolize tryptophane and arginine, respectively, and exert proapoptotic and antiproliferative effects on T-cells. Plasma levels of IDO and ARG and their relation to blood T-cell number were evaluated in HD patients.
METHODS: Thirty-two HD patients and 20 healthy controls participated in the study. Plasma IDO and ARG were measured by means of enzyme-linked immunosorbent assay. T-cell number was assessed by means of flow cytometry.
RESULTS: IDO concentration was significantly higher in HD patients than in healthy volunteers (44.30 ± 31.83 ng/mL vs. 21.28 ± 26.21 ng/mL, p = 0.009). There was a trend for higher ARG concentration in HD patients (13.43 ± 11.91 ng/mL) than in healthy volunteers (9.56 ± 4.03 ng/mL), which, however, did not reach statistic significance (p = 0.099). Absolute T-cell count was significantly lower in HD patients than in healthy controls (1176.99 ± 567.71 cells/mm3 vs. 1519.85 ± 594.96 cells/mm3, p = 0.040). Absolute blood T-cell number was inversely related to plasma IDO (r = -0.490, p = 0.004) and to plasma ARG (r = -0.387, p = 0.029) concentrations.
CONCLUSIONS: Plasma IDO and ARG may contribute to decreased blood T-cell count in HD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897519     DOI: 10.3109/0886022X.2012.713297

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

1.  Decreased percentage of peripheral naïve T cells is independently associated with ischemic stroke in patients on hemodialysis.

Authors:  Rongyi Chen; Jiachang Hu; Fangfang Xiang; Xiao Tan; Bo Shen; Zhonghua Liu; Wenlv Lv; Xiaoqiang Ding; Xuesen Cao; Jianzhou Zou
Journal:  Int Urol Nephrol       Date:  2017-09-15       Impact factor: 2.370

2.  Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Immunology       Date:  2015-07-27       Impact factor: 7.397

3.  Serum osteoprotegerin is markedly increased and may contribute to decreased blood T cell count in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Efi Yiannaki; Vassilios Liakopoulos; Georgia Antoniadi; Georgios Pissas; Grammati Galaktidou; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

4.  Plasma metabolomics profiling of maintenance hemodialysis based on capillary electrophoresis - time of flight mass spectrometry.

Authors:  Shuxin Liu; Lichao Wang; Chunxiu Hu; Xin Huang; Hong Liu; Qiuhui Xuan; Xiaohui Lin; Xiaojun Peng; Xin Lu; Ming Chang; Guowang Xu
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

5.  Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.

Authors:  Yuanhan Chen; Zhen Xie; Chenggen Xiao; Min Zhang; Zhilian Li; Jianteng Xie; Yusheng Zhang; Xingchen Zhao; Pengfei Zeng; Liyi Mo; Xinling Liang; Wei Shi
Journal:  Oncotarget       Date:  2017-04-11

6.  Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.

Authors:  Christina Wefers; Gerty Schreibelt; Leon F A G Massuger; I Jolanda M de Vries; Ruurd Torensma
Journal:  Front Immunol       Date:  2018-06-19       Impact factor: 7.561

7.  Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.

Authors:  Lisa Christiansson; Stina Söderlund; Emma Svensson; Satu Mustjoki; Mats Bengtsson; Bengt Simonsson; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.